Resolution of inflammation during multiple sclerosis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a frequent autoimmune demyelinating disease of the central nervous system (CNS). There are three clinical forms described: relapsing-remitting multiple sclerosis (RRMS), the most common initial presentation (85%) among which, if not treated, about half will transform, into the secondary progressive multiple sclerosis (SPMS) and the primary progressive MS (PPMS) (15%) that is directly progressive without superimposed clinical relapses. Inflammation is present in all subsets of MS. The relapsing/remitting form could represent itself a particular interest for the study of inflammation resolution even though it remains incomplete in MS. Successful resolution of acute inflammation is a highly regulated process and dependent on mechanisms engaged early in the inflammatory response that are scarcely studied in MS. Moreover, recent classes of disease-modifying treatment (DMTs) that are effective against RRMS act by re-establishing the inflammatory imbalance, taking advantage of the pre-existing endogenous suppressor. In this review, we will discuss the active role of regulatory immune cells in inflammation resolution as well as the role of tissue and non-hematopoietic cells as contributors to inflammation resolution. Finally, we will explore how DMTs, more specifically induction therapies, impact the resolution of inflammation during MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“The infiltration of pro-inflammatory leukocytes in the CNS further triggers a disruption of the myelin sheath eventually leading to neuronal loss [2].”
BackgroundB cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647 · cited 1×
“Further studies showed that transfer of B10 cells in mice suppresses active and spontaneous EAE in different mouse strains [49, 50].”
BackgroundReboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206 · cited 3×
“The CCL20 chemokine ligand of CCR6 is constitutively expressed at the choroid plexus [132].”
BackgroundShen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Hong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000 · cited 1×
“However, SPMs are produced in different tissues including the brain and cerebrospinal fluid [100] and accumulative evidence reveal that SPMs reduce neurodegenerative disease and protect neural cells in ischemic stroke or Alzheimer’s disease [101, 102].”
BackgroundThe Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence
Alvarez, J. I., Dodelet-Devillers, A., Kebir, H., Ifergan, I., Fabre, P. J., Terouz, S., Sabbagh, M., Wosik, K., Bourbonnière, L., Bernard, M., et al. (2011) · Science · doi:10.1126/science.1206936 · Cited by 845
Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305841200 · Cited by 802 · cited 1×
“However, SPMs are produced in different tissues including the brain and cerebrospinal fluid [100] and accumulative evidence reveal that SPMs reduce neurodegenerative disease and protect neural cells in ischemic stroke or Alzheimer’s disease [101, 102].”
BackgroundApetoh, L., Quintana, F. J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E. J., Sherr, D. H., Weiner, H. L., & Kuchroo, V. K. (2010) · Nature Immunology · doi:10.1038/ni.1912 · Cited by 725
Self-citationExperimental Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient Mice
Wolf, S. D., Dittel, B. N., Hardardottir, F., & Janeway, C. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2271 · Cited by 699 · cited 1×
“The role of B cells itself remained elusive for many years, and initially, it was proposed using B cell-deficient mice, that B cells did not play a major role in the activation of encephalitogenic T cells but may solely partially contribute to the immune modulation in EAE [46].”
BackgroundAn updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692 · cited 1×
“In all MS lesions type, the macrophages/microglia outnumber the lymphocytes [75].”
BackgroundShechter, R., Miller, O., Yovel, G., Rosenzweig, N., London, A., Ruckh, J., Kim, K.-W., Klein, E., Kalchenko, V., Bendel, P., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.012 · Cited by 683 · cited 5×
“Bregs secrete IL-35 and TGF-β that suppress APC function.”
BackgroundInfluentialThe neurovascular unit - concept review
Muoio, V., Persson, P. B., & Sendeski, M. M. (2014) · Acta Physiologica · doi:10.1111/apha.12250 · Cited by 564 · cited 1×
“Together, these cells form the neurovascular unit (NVU) [110].”
BackgroundMachado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10
Rojas, O. L., Pröbstel, A.-K., Porfilio, E. A., Wang, A. A., Charabati, M., Sun, T., Lee, D. S. W., Galicia, G., Ramaglia, V., Ward, L. A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.035 · Cited by 382
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis
Boven, L. A., Van Meurs, M., Van Zwam, M., Wierenga-Wolf, A., Hintzen, R. Q., Boot, R. G., Aerts, J. M., Amor, S., Nieuwenhuis, E. E., & Laman, J. D. (2006) · Brain · doi:10.1093/brain/awh707 · Cited by 353 · cited 3×
“When challenged with LPS, macrophages that have ingested myelin showed reduced production of the pro-inflammatory cytokines TNFα, IL-12p35, and IL-12/23p40 as compared to macrophages that have not ingested myelin [66].”
BackgroundMechanisms and Consequences of Defective Efferocytosis in Atherosclerosis
Yurdagul, A., Doran, A. C., Cai, B., Fredman, G., & Tabas, I. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00086 · Cited by 300 · cited 1×
“For example, even if it is purely speculative, the DEL-1 mutation associated with MS [135] could result in a loss of function leading to enhanced leukocyte adhesion and transmigration across the BBB while at the same time, it could contribute to disrupting efferocytosis, an important process for inflammation resolutio…”
BackgroundMerkler, D. (2006) · Brain · doi:10.1093/brain/awl135 · Cited by 222 · cited 1×
“Interestingly, an alternative rat EAE model that induces focal cortical demyelinating lesions could highlight that rapid resolution of inflammation contributes to more efficient remyelination [150].”
BackgroundAstrocytic tight junctions control inflammatory CNS lesion pathogenesis
Horng, S., Therattil, A., Moyon, S., Gordon, A., Kim, K., Argaw, A. T., Hara, Y., Mariani, J. N., Sawai, S., Flodby, P., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91301 · Cited by 221 · cited 2×
“Conditional mouse model deficient for CLDN4 in astrocytes leads to increased lesion sizes an increased number of infiltrating CD4 T cells per mm(2) of lesions during EAE [122].”
BackgroundPro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204
Netrin 1 regulates blood–brain barrier function and neuroinflammation
Podjaski, C., Alvarez, J. I., Bourbonniere, L., Larouche, S., Terouz, S., Bin, J. M., Lécuyer, M.-A., Saint-Laurent, O., Larochelle, C., Darlington, P. J., et al. (2015) · Brain · doi:10.1093/brain/awv092 · Cited by 185
Type 1 regulatory T cells (Tr1) in autoimmunity
Pot, C., Apetoh, L., & Kuchroo, V. K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.005 · Cited by 171
Self-citationPerriot, S., Mathias, A., Perriard, G., Canales, M., Jonkmans, N., Merienne, N., Meunier, C., El Kassar, L., Perrier, A. L., Laplaud, D.-A., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.09.015 · Cited by 171
Wang, Z., Brandt, S., Medeiros, A., Wang, S., Wu, H., Dent, A., & Serezani, C. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115855 · Cited by 169 · cited 1×
“Myelin uptake also increased the production of prostaglandin E2 and CCL18, two mediators that skew macrophages toward an M2 anti-inflammatory phenotype [69, 70].”
BackgroundMadsen, P. M., Motti, D., Karmally, S., Szymkowski, D. E., Lambertsen, K. L., Bethea, J. R., & Brambilla, R. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0211-16.2016 · Cited by 161
The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum
Schraufstatter, I. U., Zhao, M., Khaldoyanidi, S. K., & DiScipio, R. G. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03541.x · Cited by 144
Cited by
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
miR-181a-5p is a potential candidate epigenetic biomarker in multiple sclerosis
Edgünlü, T. G., Yılmaz, Ş. G., Emre, U., Taşdelen, B., Kuru, O., Kutlu, G., & Erdal, M. E. (2022) · Genome · doi:10.1139/gen-2022-0040 · Cited by 14
An Overview of Multiple Sclerosis In Vitro Models
Czpakowska, J., Kałuża, M., Szpakowski, P., & Głąbiński, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147759 · Cited by 7
“The enduring inflammation, whose causes are still unknown, contributes to demyelination and, consequently, degradation of neurons [2].”
BackgroundInfluentialUcar, E. A., Ozkan, E., Shomalizadeh, N., Sekerdağ-Kilic, E., Akpunar, F., Sapanci, S., Kesibi, J., Ozler, C., Bilgez, A. S., & Gursoy-Ozdemir, Y. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1403974 · Cited by 5
“%) type of the disease (Ruiz et al., 2019).”
Metadata
- Authors
- Ruiz, F., Vigne, S., & Pot, C.
- Venue
- Seminars in Immunopathology
- Published
- 2019-11
- Volume
- 41
- Issue
- 6
- Pages
- 711-726
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2988610115
- Cited by
- 129
- References
- 27
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.